Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-05
2006-12-05
Andres, Janet L. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007940
Reexamination Certificate
active
07144708
ABSTRACT:
The present invention relates generally to a peripheral marker or markers of blood barrier integrity and methods of using same in the diagnosis, prognosis, and treatment of a variety of diseases. The peripheral marker(s) of the present invention are particularly useful in the differential diagnosis of diseased states. The preferred embodiments of the present invention relate to methods, compositions, kits, and assays useful in determining the integrity or permeability of either a blood CSF barrier or a blood brain barrier. The various embodiments of the present invention can be used to identify subjects at risk for developing a disease associated with increased permeability of the blood brain barrier, as well as to provide insight on the ability of an agent or agents to pass through the blood brain barrier. Embodiments of the present invention preferably involve the use of subject derived blood samples to determine the occurrence and level of circulating proteins indicative of blood brain barrier permeability or integrity. The embodiments of the present invention also provides screening methods for diagnosis, prognosis, susceptibility, or degree of permeability of penetration of the blood brain barrier by detecting the presence of serum Transthyretin either directly or through the use of antibodies.
REFERENCES:
patent: 5304367 (1994-04-01), Biegon
patent: 5866347 (1999-02-01), Swedo et al.
patent: 6117989 (2000-09-01), Bandman et al.
patent: 6268223 (2001-07-01), Cornell-Bell et al.
Power et al. Evolution of the Thyroid Hormone-Binding Protein, Transthyretin. Gen. Comp. Endocrinol. 119: 241-255, 2000.
Tumor Markers in Peripheral Blood of Patients with Malignant Melanoma: Multimarker RT-PCR Versus a Luminoimmunometric Assay for S-100; Berking, Carola et al.; Arch Dermatol Res (1999) 291: 479-484.
Evaluation of Serum Markers of Neuronal Damage Following Severe Hypoglycaemia in Adults with Insulin-Treated Diabetes Mellitus; Strachan, Mark, W., et al.; Diabetes/Metabolism Research & Reviews 1999; 15: 5-12.
Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means; Kroll, Robert A. & Neuwelt, Edward A.; Neurosurgery, vol. 42, No. 5; May 1998.
Autoantibodies in Neurodegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis; Terryberry, J.W., et al.; Neurobiology of Aging, vol. 19, No. 3, pp. 205-216, 1998.
Cerebrospinal Fluid Analysis Differentiates Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis; Jongen, Peter J. H. et al.; Neurol Neurosurg Psychiatry 1997; 63: 446-451.
S-100 Release in Hypothermic Circulatory Arrest and Coronary Artery Surgery; Wong, Carl H. et al.; Ann Thorac Surg 1999; 67: 1911-4.
Serum S100 Protein: A Potential Marker for Cerebral Events During Cardiopulmonary Bypass; Westaby, Stephen et al.; Ann Thorac Surg 1996; 61: 88-92.
Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia; Mecocci, P. et al.; Journal of Neuroimmunology 57 (1995) 165-170.
Uncontrolled Reoxygenation by Initiating Cardiopulmonary bypass is Associated with Higher Protein S-100 in Cyanotic Versus Acyanotic Patients; Matheis, G. et al.; Thorac Cardiov Surg 2000; 48: 263-268.
Missler et al. (Jul. 1, 2000) “Validation and Comparison of Two Solid-Phase Immunoassays for the Quantification of S-100b in Human Blood.” Clinical Chemistry 46(7): 993-996.
Takahashi et al. (Aug. 1, 1999) “Rapid and Sensitive Immunoassay for the Measurement of Serum S100b Using Isoform-specific Monoclonal Antibody.” Clinical Chemistry 45(8): 1307-1311.
Herrmann et al. (2000) “Release of Glial Tissue-Specific Proteins After Acute Stroke.” Stroke 31: 2670-2677.
Marchi et al. (2003) “Serum Transthyretin Monomer as a Possible Marker of Blood-to-CSF Barrier Disruption.” The Jour. of Neuroscience 23(5):1949-1955.
Bonfrer, JM, Korse, CM<Nieweg, OE, Rankin, EM (1998) The luminescence immunoassay S-100: a sensitive test to measure ciculating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77: 2210-2214.
Borchez L, Naeyaert JM (2000) Serological markers for melanoma, Br J Dermatol 143: 256-268.
Buccoliero AM, Caldarella A, Noccioli B, Fiorini P, Taddei A, Taddei GL (2002) Brain hetertopia in pharyngeal region. A morphological and immunohistochemical study. Pathol Res Pract 198: 59-63.
Chakrabarty A, Franks AJ (1999) Meningioangiogmatosis: a case report and review of the litaterature. Br J Neurosurg 13: 167-173.
Crossen JR, Goldman DL, Dahlborg SA, Neuwelt EA (1992) Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotheraphy. Neurosurgery 30: 23-29.
Davidsson P, Paulson L, Hesse C, Blennow K, Nilsson CL (2001) Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics 1: 444-452.
Davson H, Segal MB (1995) The proteins and other macromolecules of the CSF, In: Physiology of the CSF and of the blood-brain barrier (Davson H, Segal MB, eds), pp. 573-606. New York, NY: CRC.
Dyck RH, Van Eldik LJ, Cynader MS (1993) Immunohistochemical localization of the S-100 beta protein in postnatal cat visual cortex: spatial and temporal patterns of expression in cortical and subcortical glia. Brian Res Dev Brain Res 72: 181-192.
Feany MB, Anthony DC, Fletcher CD (1998) Nerve sheath tumours with hybrid features of neurofibroma and schwannoma: a conceptual challenge. Histopathology 32: 405-410.
Grocott HP, Arrowsmith JE (2001) Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth 86: 289-290.
Grocott HP, Laskowitz DT, Newman MF (2001) Markers of cerebral injury. In: The brain and cardiac surgery (Newman. SP, Harrison MJG, eds), pp. 113-142. Amsterdam, NL: Harwood Academic Publishers.
Hamilton JA, Benson MD (2001) Transthyretin: a review from a structural perspective. Cell Mol Life Sci 58: 1491-1521.
Herbert J, Wilcox JN, Pham KT, Fremeau RT, Jr., Zeviani M, Dwork A. Soprano DR, Makover A, Goodman DS, Zimmerman EA,. (1986) Transthyretin: a choroids plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology 36: 900-911.
Hiraoka A, Tominaga I, Hori K (2000) Sodium dodecylsulfate capillary gel electrophoretic measurement of the concentration ratios of albumin and alpha2-macroglobulin in cerebrospinal fluid and serum of patients with neurological disorders. J Chromatogr A 895: 339-344.
Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 56: 431-435.
Ingebrigsten T, Romner B, Marup-Jensen S, Dons M, Lundqvist C, Bellner J, Alling C, Borgesen SE (2000) The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 14: 1047-1055.
Ingebrigtsen T, Waterloo K, Jacobsen EA, Langbakk B, Romner B (1999) Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery 45: 468-475.
Janigro, D., Fazio, V., Cucullo, L., and Marchi, N. Markers of BBB damage and inflammatory processes. Soc.for Neuroscience Annual Meeting 580.9 2002.
Jonsson H. Johnsson P, Alling C, Westaby S, Blomquist S (1998) Significance of serum S100 release after coronary artery bypass grafting. Ann Thorac Surg 65: 1639-1644.
Kapural M, Bengez L, Barnett G, Perl J, II, Masaryk TJ, Apollo D, Mayberg MR, Janigro D (2002) S-100B as a possible serum marker for disruption on the blood-brain barrier. Brain Res 940: 102-104.
Mercier F, Hatton GI (2000) Immunocytochemical basis for a meningeo-glial network. J Comp Neurol 420: 445-465.
Molloy MP (2000) Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal Biochem 280: 1-10.
Monaco HL (2000) The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 1482: 65-72.
Mrak RE, F
Janigro Damir
Marchi Nicola
Andres Janet L.
Emch Gregory S
Hamilton Brook Smith & Reynolds P.C.
The Cleveland Clinic Foundation
LandOfFree
Markers of blood barrier disruption and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers of blood barrier disruption and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers of blood barrier disruption and methods of using same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698383